CYP2D6 phenotype, tamoxifen, and risk of contralateral breast cancer in the WECARE Study

Abstract Background Tamoxifen treatment greatly reduces a woman’s risk of developing a second primary breast cancer. There is, however, substantial variability in treatment response, some of which may be attributed to germline genetic variation. CYP2D6 is a key enzyme in the metabolism of tamoxifen...

Fuld beskrivelse

Bibliografiske detaljer

Principais autores:	Jennifer D. Brooks, Elizabeth A. Comen, Anne S. Reiner, Irene Orlow, Siok F. Leong, Xiaolin Liang, Lene Mellemkjær, Julia A. Knight, Charles F. Lynch, Esther M. John, Leslie Bernstein, Meghan Woods, David R. Doody, The WECARE Study collaborative group, Kathleen E. Malone, Jonine L. Bernstein
Format:	Artigo
Sprog:	Inglês
Udgivet:	BMC 2018-12-01
Serier:	Breast Cancer Research
Fag:	Contralateral breast cancer Tamoxifen CYP2D6
Online adgang:	http://link.springer.com/article/10.1186/s13058-018-1083-y
Tags:	Tilføj Tag Ingen Tags, Vær først til at tagge denne postø!